GPB Scientific Announces Additional Growth Financing to Support Commercialization of Curate™ Cell Processing System for Next-Generation Cell & Gene Therapies
Retrieved on:
Thursday, May 27, 2021
Research, FDA, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Branches of biology, T cells, Clinical medicine, Biotechnology, Immune system, Medicine, Bioprocess, Chimeric antigen receptor T cell, TRA, GBP Scientific, Vensana Capital, Amgen Ventures, GBP SCIENTIFIC, VENSANA CAPITAL, AMGEN VENTURES
This financing will support expanded placements of GPBs Curate Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platforms utility in additional types of cell and gene therapy applications.
Key Points:
- This financing will support expanded placements of GPBs Curate Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platforms utility in additional types of cell and gene therapy applications.
- The Curate system utilizes GPBs proprietary Deterministic Cell Separation technology to deliver unmatched recovery, purity, and cell health impacting each of these challenges in bioprocessing for cell and gene therapies.
- He commented, "The Curate system is poised to be transformative for cell and gene therapies.
- GPB Scientific is a pioneering biomedical company realizing the promise of its Curate Cell Processing System.